Guastella, J. et al. Cloning and expression of a rat brain GABA transporter. Science 249, 1303–1306 (1990).
Madsen, K. K., White, H. S. & Schousboe, A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol. Ther. 125, 394–401 (2010).
Braestrup, C. et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J. Neurochem. 54, 639–647 (1990).
Blat, Y. Non-competitive inhibition by active site binders. Chem. Biol. Drug Des. 75, 535–540 (2010).
Sieghart, W. Structure, pharmacology, and function of GABAA receptor rubtypes. GABA 54, 231–263 (2006).
Bowery, N. G. et al. International Union of Pharmacology. XXXIII. Mammalian γ-aminobutyric acidB receptors: structure and function. Pharmacol. Rev. 54, 247–264 (2002).
Fattorini, G., Melone, M. & Conti, F. A reappraisal of GAT-1 localization in neocortex. Front. Cell. Neurosci. 14, 9 (2020).
Roberts, B. M. et al. GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model. Nat. Commun. 11, 4958 (2020).
Mermer, F. et al. Common molecular mechanisms of SLC6A1 variant-mediated neurodevelopmental disorders in astrocytes and neurons. Brain 144, 2499–2512 (2021).
Rosenthal, M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J. Clin. Psychiatry 64, 1245–1249 (2003).
Lyu, S. et al. Blockade of GABA transporter-1 and GABA transporter-3 in the lateral habenula improves depressive-like behaviors in a rat model of Parkinson’s disease. Neuropharmacology 181, 108369 (2020).
Fuhrer, T. E. et al. Impaired expression of GABA transporters in the human Alzheimer’s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus. Neuroscience 351, 108–118 (2017).
Paparrigopoulos, T., Tzavellas, E., Karaiskos, D., Malitas, P. & Liappas, I. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. J. Psychopharmacol. 24, 1375–1380 (2010).
Schwartz, T. L. et al. An open-label study of tiagabine as augmentation therapy for anxiety. Ann. Clin. Psychiatry 17, 167–172 (2005).
Carpenter, L. L. et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J. Clin. Psychiatry 67, 66–71 (2006).
Kragholm, B. et al. Discovery of a subtype selective inhibitor of the human betaine/GABA transporter 1 (BGT-1) with a non-competitive pharmacological profile. Biochem. Pharmacol. 86, 521–528 (2013).
Hauke, T. J., Wein, T., Höfner, G. & Wanner, K. T. Novel allosteric ligands of γ-aminobutyric acid transporter 1 (GAT1) by MS based screening of pseudostatic hydrazone libraries. J. Med. Chem. 61, 10310–10332 (2018).
Jurik, A. et al. A binding mode hypothesis of tiagabine confirms liothyronine effect on γ-aminobutyric acid transporter 1 (GAT1). J. Med. Chem. 58, 2149–2158 (2015).
Zafar, S. & Jabeen, I. Molecular dynamic simulations to probe stereoselectivity of tiagabine binding with human GAT1. Molecules 25, 4745 (2020).
Skovstrup, S., David, L., Taboureau, O. & Jørgensen, F. S. A steered molecular dynamics study of binding and translocation processes in the GABA transporter. PLoS ONE 7, e39360 (2012).
Keynan, S., Suh, Y. J., Kanner, B. I. & Rudnick, G. Expression of a cloned gamma-aminobutyric acid transporter in mammalian cells. Biochemistry 31, 1974–1979 (1992).
Cammack, J. N., Rakhilin, S. V. & Schwartz, E. A. A GABA transporter operates asymmetrically and with variable stoichiometry. Neuron 13, 949–960 (1994).
Lester, H. A., Mager, S., Quick, M. W. & Corey, J. L. Permeation properties of neurotransmitter transporters. Annu. Rev. Pharmacol. Toxicol. 34, 219–249 (1994).
Jardetzky, O. Simple allosteric model for membrane pumps. Nature 211, 969–970 (1966).
Krishnamurthy, H. & Gouaux, E. X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature 481, 469–474 (2012).
Penmatsa, A., Wang, K. H. & Gouaux, E. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503, 85–90 (2013).
Gotfryd, K. et al. X-ray structure of LeuT in an inward-facing occluded conformation reveals mechanism of substrate release. Nat. Commun. 11, 1005 (2020).
Singh, S. K., Yamashita, A. & Gouaux, E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448, 952–956 (2007).
Coleman, J. A., Green, E. M. & Gouaux, E. X-ray structures and mechanism of the human serotonin transporter. Nature 532, 334–339 (2016).
Coleman, J. A. et al. Serotonin transporter–ibogaine complexes illuminate mechanisms of inhibition and transport. Nature 569, 141–145 (2019).
Shahsavar, A. et al. Structural insights into the inhibition of glycine reuptake. Nature 591, 677–681 (2021).
Zhou, Z. et al. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317, 1390–1393 (2007).
Kantcheva, A. K. et al. Chloride binding site of neurotransmitter sodium symporters. Proc. Natl Acad. Sci. USA 110, 8489–8494 (2013).
Li, F. et al. Ion transport and regulation in a synaptic vesicle glutamate transporter. Science 368, 893–897 (2020).
Zimmermann, I. et al. Synthetic single domain antibodies for the conformational trapping of membrane proteins. eLife 7, e34317 (2018).
Tsutsumi, N. et al. Structure of human Frizzled5 by fiducial-assisted cryo-EM supports a heterodimeric mechanism of canonical Wnt signaling. eLife 9, e58464 (2020).
Wu, X. & Rapoport, T. A. Cryo-EM structure determination of small proteins by nanobody-binding scaffolds (Legobodies). Proc. Natl Acad. Sci. USA 118, e2115001118 (2021).
Borden, L. A. et al. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur. J. Pharmacol. 269, 219–224 (1994).
Suzdak, P. D., Foged, C. & Andersen, K. E. Quantitative autoradiographic characterization of the binding of [3H]tiagabine (NNC 05-328) to the GABA uptake carrier. Brain Res. 647, 231–241 (1994).
Korkhov, V. M., Farhan, H., Freissmuth, M. & Sitte, H. H. Oligomerization of the γ-aminobutyric acid transporter-1 is driven by an interplay of polar and hydrophobic interactions in transmembrane helix II. J. Biol. Chem. 279, 55728–55736 (2004).
White, H. S. et al. Correlation between anticonvulsant activity and inhibitory action on glial gamma-aminobutyric acid uptake of the highly selective mouse gamma-aminobutyric acid transporter 1 inhibitor 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and its N-alkylated analogs. J. Pharmacol. Exp. Ther. 302, 636–644 (2002).
Malinauskaite, L. et al. A mechanism for intracellular release of Na+ by neurotransmitter/sodium symporters. Nat. Struct. Mol. Biol. 21, 1006–1012 (2014).
Ben-Yona, A. & Kanner, B. I. Functional defects in the external and internal thin gates of the γ-aminobutyric acid (GABA) transporter GAT-1 can compensate each other. J. Biol. Chem. 288, 4549–4556 (2013).
Bismuth, Y., Kavanaugh, M. P. & Kanner, B. I. Tyrosine 140 of the gamma-aminobutyric acid transporter GAT-1 plays a critical role in neurotransmitter recognition. J. Biol. Chem. 272, 16096–16102 (1997).
Dhar, T. G. et al. Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3. J. Med. Chem. 37, 2334–2342 (1994).
Kanner, B. I. Transmembrane domain I of the gamma-aminobutyric acid transporter GAT-1 plays a crucial role in the transition between cation leak and transport modes. J. Biol. Chem. 278, 3705–3712 (2003).
Rudnick, G. Forty four years with Baruch Kanner and the chloride ion. Neurochem. Res. 47, 3–8 (2022).
Wang, K. H., Penmatsa, A. & Gouaux, E. Neurotransmitter and psychostimulant recognition by the dopamine transporter. Nature 521, 322–327 (2015).
Bulling, S. et al. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J. Biol. Chem. 287, 18524–18534 (2012).
Alberati, D. et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 62, 1152–1161 (2012).
Wang, X., Ratnaraj, N. & Patsalos, P. N. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure 13, 574–581 (2004).
Sandtner, W. et al. Binding mode selection determines the action of ecstasy homologs at monoamine transporters. Mol. Pharmacol. 89, 165–175 (2016).
Clausen, R. P. et al. Structure–activity relationship and pharmacology of gamma-aminobutyric acid (GABA) transport inhibitors. Adv. Pharmacol. 54, 265–284 (2006).
Reith, M. E. A. et al. Novel C-1 substituted cocaine analogs unlike cocaine or benztropine. J. Pharmacol. Exp. Ther. 343, 413–425 (2012).
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
Alexandrov, A. I., Mileni, M., Chien, E. Y. T., Hanson, M. A. & Stevens, R. C. Microscale fluorescent thermal stability assay for membrane proteins. Structure 16, 351–359 (2008).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214–1221 (2020).
Bordoli, L. et al. Protein structure homology modeling using SWISS-MODEL workspace. Nat. Protoc. 4, 1–13 (2009).
Goddard, T. D., Huang, C. C. & Ferrin, T. E. Visualizing density maps with UCSF Chimera. J. Struct. Biol. 157, 281–287 (2007).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D60, 2126–2132 (2004).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).
Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D 74, 531–544 (2018).
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12–21 (2010).
Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2, 19–25 (2015).
Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29, 1859–1865 (2008).
Kim, S. et al. CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules. J. Comput. Chem. 38, 1879–1886 (2017).
Leonard, A. N. & Lyman, E. Activation of G-protein-coupled receptors is thermodynamically linked to lipid solvation. Biophys. J. 120, 1777–1787 (2021).
Lomize, M. A., Pogozheva, I. D., Joo, H., Mosberg, H. I. & Lomize, A. L. OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res. 40, D370–D376 (2012).
McGibbon, R. T. et al. MDTraj: a modern open library for the analysis of molecular dynamics trajectories. Biophys. J. 109, 1528–1532 (2015).
DeLano, W. L. Pymol: an open-source molecular graphics tool. CCP4 http://legacy.ccp4.ac.uk/newsletters/newsletter40/11_pymol.html (2002).
Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14–25 (2018).
More News
Measuring the forces that shape early human embryos
Natural killer cells show their cancer-fighting worth
More than a billion people live in ‘energy poverty’